Outcome measures include neurological severity scoring, rotarod and beam walk performance, histological assessment of lesion volume, and immunohistochemistry for axonal markers and myelin basic protein
The peptide increased decorin production by 302% and stimulated glycosaminoglycan accumulation in skin fibroblasts
The peptide also appears to interact with pain signaling pathways in the central nervous system, offering relief from both inflammatory and non-inflammatory pain
It is not approved for human or animal use, and may not be used in food, drugs, cosmetics, or diagnostic applications
no human cases confirmed) Long-term Safety: SELECT trial demonstrated 5+ year cardiovascular safety Key Difference: AOD-9604 may have a cleaner tolerability profile (no GI effects), but efficacy failure makes this advantage clinically irrelevant